Tenon Medical (TNON) director discloses RSU conversion and stock sale

Rhea-AI Filing Summary

Tenon Medical, Inc. director reports RSU vesting and share sale

A director of Tenon Medical, Inc. (TNON) reported equity transactions involving restricted stock units and common stock. On January 1, 2026, 10,732 restricted stock units converted into 10,732 shares of common stock, increasing the director’s holdings. On January 5, 2026, 3,327 shares of common stock were disposed of at a price of $0.9301 per share to satisfy tax liabilities related to the RSU vesting. Following these transactions, the director directly held 8,462 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HOWARD IVAN

(Last) (First) (Middle)

104 COOPER COURT

(Street)

LOS GATOS CA 95032

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/01/2026		M		10,732	A	$0	11,789	D
Common Stock(2)	01/05/2026		F		3,327	D	$0.9301	8,462	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units(1)	(3)	01/01/2026		M			10,732	(1)	(1)	Common Stock	10,732	$0	10,732	D

Explanation of Responses:

1. Represents conversion of 10,732 restricted stock units ("RSUs") granted to the reporting person on October 13, 2025 into 10,732 shares of common stock of the Issuer on January 1, 2026.

2. These shares were sold to pay tax liability associated with the vesting of RSUs.

3. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

	/s/ Ivan Howard	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tenon Medical (TNON) report in this Form 4?

A director of Tenon Medical, Inc. reported the conversion of 10,732 restricted stock units into common shares on January 1, 2026, and a related sale of shares on January 5, 2026.

How many Tenon Medical (TNON) RSUs vested in this filing and when?

10,732 restricted stock units granted on October 13, 2025 vested and were converted into 10,732 shares of common stock on January 1, 2026.

How many Tenon Medical (TNON) shares were sold and at what price?

The director sold 3,327 shares of common stock on January 5, 2026 at a price of $0.9301 per share to cover tax liabilities from the RSU vesting.

How many Tenon Medical (TNON) shares does the insider own after these transactions?

After the reported transactions, the director directly beneficially owned 8,462 shares of Tenon Medical common stock.

What is the relationship of the reporting person to Tenon Medical (TNON)?

The reporting person is a director of Tenon Medical, Inc., as indicated in the relationship section of the filing.

What does each Tenon Medical (TNON) restricted stock unit represent in this filing?

Each restricted stock unit represents a contingent right to receive one share of common stock of Tenon Medical, as described in the explanation of responses.